In this presentation, CEO Chris Coughlin and Chief Medical Officer David Liebowitz provide an update for investors on the Phase 1a data for faridoxorubicin presented at the European Society of Medical Oncology Annual Congress.
In this presentation, CEO Chris Coughlin and Chief Medical Officer David Liebowitz provide an update for investors on the Phase 1a data for faridoxorubicin presented at the European Society of Medical Oncology Annual Congress.